AI-generated analysis. Always verify with the original filing.
Kezar Life Sciences terminated its office lease early for ~$2M and entered separation agreements with CEO Kirk, CFO Belsky, and COO Schiller tied to a pending merger with Aurinia Pharma.
Event Type
Disclosure
Mandatory
Variant
8-K
Termination of a Material Definitive Agreement. On April 1, 2026, Kezar Life Sciences, Inc. (the “Company”) entered into a lease termination agreement (the “Lea
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On April 1, 2
Financial Statements and Exhibits. (d) Exhibits Exhibit No.: 10.1 | Description: Lease Termination Agreement, dated as of April 1, 2026, by and between the Comp
Christopher J. Kirk, Ph.D.
Effective: Separation Date (merger closing or earlier)
Transaction-related
Marc L. Belsky
Effective: Separation Date (merger closing or earlier)
Transaction-related
Mark Schiller
Effective: Separation Date (merger closing or earlier)
Transaction-related
Material Agreement